Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Abeona Therapeutics Inc (ABEO) vs Zillow Group Inc Class C (Z) Price & Performance

Abeona Therapeutics IncTrade
Zillow Group Inc Class CTrade

Price performance (Past 24H)

Key statistics

Abeona Therapeutics Inc vs Zillow Group Inc Class C — how do they compare? Abeona Therapeutics Inc trades at $7.38 (market cap $421.19M), while Zillow Group Inc Class C trades at $32.73 (market cap $7.68B). The key difference: Zillow Group Inc Class C is far larger — about 18.2× Abeona Therapeutics Inc's market cap, and Abeona Therapeutics Inc is trading nearer its 52-week high, Zillow Group Inc Class C nearer its low. Which is the better fit depends on your goals.

ABEOZ
Market Cap
$421.19M$7.68B
Sector
HealthMedia
52-Week High
$7.45$90.35
52-Week Low
$4.17$29.41
Enterprise Value
$276.10M$7.56B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Abeona Therapeutics Inc

ABEO trades at $7.365, down 1.14% today, amid a bullish technical outlook with moving averages signaling strength. The company reported a net income of $71.18 million in 2025, with a net margin of 454.86%, though revenue remains modest at $5.82 million. Recent news includes CMS granting NTAP status for ZEVASKYN and expanding its treatment center network, indicating commercial progress.

The outlook is supported by strong analyst consensus (66.7% buy ratings) and robust profitability metrics, but risks include high SG&A expenses relative to revenue and a shareholder investigation. Upside hinges on revenue scaling to justify current valuations, with the Q2 2026 earnings call on August 13, 2026, as a key near-term catalyst.

Zillow Group Inc Class C

Zillow Group (Z) trades at $33.48, down 0.8% on the day, amid mixed technical signals and ongoing securities litigation. The company shows improving fundamentals with Q2 2026 revenue growth of 18% and consecutive earnings beats, though net margins remain thin at 1.96%. Analyst consensus is divided with a $52 price target representing 55% upside potential from current levels.

While Zillow demonstrates operational improvement and strong monetization growth, significant headwinds include multiple class-action lawsuits and bearish technical indicators. The stock offers substantial upside if legal concerns resolve favorably, but near-term volatility persists due to legal overhang and competitive real estate market pressures.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Abeona Therapeutics Inc

Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.

Read more on ABEO

About Zillow Group Inc Class C

Zillow Group is an online real estate company that simplifies buying, selling, renting, and financing properties. It partners with agents, brokers, and landlords, combining technology with quality service. Its brands include Zillow, Trulia, StreetEasy, and Hotpads.

Read more on Z